Nyrada (ASX:NYR) Ending Cash Position: A$8.39 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:NYR Nyrada Inc ASX:NYR
23 GF Score
Price A$0.74
! 1 Warning Sign
View Full Analysis

What is Nyrada Ending Cash Position?

Nyrada ASX:NYR -6.92% 23 Ending Cash Position is A$8.39 Mil as of Jun. 2026. GuruFocus rates ASX:NYR with a GF Score™ of 23/100. The stock has 1 warning sign investors should review.

Nyrada's Ending Cash Position for the quarter that ended in Jun. 2026 was A$8.39 Mil.

Nyrada's quarterly Ending Cash Position increased from Jun. 2025 (A$2.93 Mil) to Dec. 2025 (A$7.12 Mil) and increased from Dec. 2025 (A$7.12 Mil) to Jun. 2026 (A$8.39 Mil).

Nyrada's annual Ending Cash Position declined from Jun. 2024 (A$4.77 Mil) to Jun. 2025 (A$2.93 Mil) but then increased from Jun. 2025 (A$2.93 Mil) to Jun. 2026 (A$8.39 Mil).

Nyrada Ending Cash Position Related Terms

Nyrada Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Nyrada's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nyrada Ending Cash Position Chart

Nyrada Annual Data
Trend Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
Ending Cash Position
Get a 7-Day Free Trial 10.82 3.71 4.77 2.93 8.39

Nyrada Semi-Annual Data
Jun19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.77 5.71 2.93 7.12 8.39
ASX:NYR
23GF Score
Nyrada Inc ASX:NYR
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nyrada Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Nyrada's Ending Cash Position for the fiscal year that ended in Jun. 2026 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=2.931+5.454
=8.39

Nyrada's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=7.126+1.259
=8.39

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of A$8.39 Mil mean?
Nyrada (ASX:NYR) has a Ending Cash Position of A$8.39 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Nyrada and its competitors.
Is Nyrada's Ending Cash Position too high?
Nyrada's current Ending Cash Position is A$8.39 Mil. Overall, Nyrada has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Nyrada's Ending Cash Position compare to VRTX and REGN?
Nyrada's Ending Cash Position of A$8.39 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Nyrada and its competitors. Nyrada's current Ending Cash Position is A$8.39 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nyrada stock overvalued right now?
Nyrada (ASX:NYR) has a current Ending Cash Position of A$8.39 Mil. The current Ending Cash Position is A$8.39 Mil. Nyrada's overall GF Score™ is 23/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Nyrada (ASX:NYR), the current Ending Cash Position is A$8.39 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nyrada Business Description

Address 180 George Street, Sydney Place, Level 22/23, Salesforce Tower, Sydney, NSW, AUS, 2000
Nyrada Inc is a preclinical-stage, drug discovery, and development company, specializing in novel small-molecule drugs to treat cardiovascular and neurological diseases. It operates in one segment: research and development of drugs focusing on small molecules with potential therapeutic benefit in areas of medical needs. The company's two programs center on cholesterol-lowering and brain injury, each targeting market sectors of notable size and unmet clinical needs. The programs are focused on developing an oral, small molecule cholesterol-lowering drug, and a drug to treat secondary brain damage following a stroke or traumatic brain injury.
23GF Score

Get the complete analysis for ASX:NYR

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.74
Price